Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization
Background COVID-19 patients present with delirium during their hospitalization. Aims To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. Methods COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. Results Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Discussion The use of LMWH was associated with absence of delirium, independently of comorbidities and age. Conclusions The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
---|---|
Enthalten in: |
Neurological sciences - 42(2020), 4 vom: 13. Nov., Seite 1527-1530 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
D’Ardes, Damiano [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
C reactive protein |
doi: |
10.1007/s10072-020-04887-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR043489621 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR043489621 | ||
003 | DE-627 | ||
005 | 20230520000242.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210314s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10072-020-04887-4 |2 doi | |
035 | |a (DE-627)SPR043489621 | ||
035 | |a (DE-599)SPRs10072-020-04887-4-e | ||
035 | |a (SPR)s10072-020-04887-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.90 |2 bkl | ||
100 | 1 | |a D’Ardes, Damiano |e verfasserin |4 aut | |
245 | 1 | 0 | |a Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background COVID-19 patients present with delirium during their hospitalization. Aims To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. Methods COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. Results Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Discussion The use of LMWH was associated with absence of delirium, independently of comorbidities and age. Conclusions The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae. | ||
650 | 4 | |a Delirium |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Low molecular weight heparin |7 (dpeaa)DE-He213 | |
650 | 4 | |a C reactive protein |7 (dpeaa)DE-He213 | |
700 | 1 | |a Carrarini, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Russo, Mirella |e verfasserin |4 aut | |
700 | 1 | |a Dono, Fedele |e verfasserin |4 aut | |
700 | 1 | |a Speranza, Rino |e verfasserin |4 aut | |
700 | 1 | |a Digiovanni, Anna |e verfasserin |4 aut | |
700 | 1 | |a Martinotti, Giovanni |e verfasserin |4 aut | |
700 | 1 | |a Di Iorio, Angelo |e verfasserin |4 aut | |
700 | 1 | |a Onofrj, Marco |e verfasserin |4 aut | |
700 | 1 | |a Cipollone, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Bonanni, Laura |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Milano : Springer, 2000 |g 42(2020), 4 vom: 13. Nov., Seite 1527-1530 |w (DE-627)SPR008581010 |w (DE-600)1481772-X |x 1590-3478 |7 nnns |
773 | 1 | 8 | |g volume:42 |g year:2020 |g number:4 |g day:13 |g month:11 |g pages:1527-1530 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10072-020-04887-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.90 |q ASE |
951 | |a AR | ||
952 | |d 42 |j 2020 |e 4 |b 13 |c 11 |h 1527-1530 |